GlaxoSmithKline Pharmaceuticals declared its financial results for the quarter ended December 31, 2021. Revenue for the quarter from Continuing Operations came in at Rs 808 crore recording a growth of 2%. PBT (before exceptional items) from Continuing Operations for the quarter at Rs 189 crore recorded a growth of 6%. EBITDA from Continuing Operations at Rs 197 crore recorded a growth of 8%.

Revenue from Continuing Operations for the nine months ended December 31, 2021 was Rs 2426 crore recording a growth of 11 %. PST (before exceptional items) from Continuing Operations for the nine months at Rs 585 crore recorded a growth of 27%. EBITDA from Continuing Operations at Rs 582 crore recorded a growth of 31 %.

Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals said, "GSK's established pharma portfolio recorded strong doubledigit growth, driven by our core legacy brands such as Ca/pol, Augmentin and Ceftum.”

He further added, ”While our promoted brands grew, our vaccines business was impacted on account of the third wave of the pandemic. However, as this phase of the pandemic recedes and schools open up across the country, we are witnessing a steady uptake in vaccination. We also continue to invest in our brands and raise awareness amongst parents about more innovative vaccines from our portfolio.”

“During the quarter, we concluded the sale of the Vemgal plant in Karnataka. In the subsequent quarters, we will also aim to close the transfer of lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited, as part of GSK pie's plans to create two world class companies in pharmaceuticals and consumer healthcare."